ID

35109

Description

Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02293850

Link

https://clinicaltrials.gov/show/NCT02293850

Keywords

Versions (2)
  1. 2/18/19 2/18/19 -
  2. 9/20/21 9/20/21 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

February 18, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Carcinoma, Hepatocellular NCT02293850

English

Eligibility Carcinoma, Hepatocellular NCT02293850

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. patients aged 18 to 65 years (19 to 65 years in korea) in phase i part or aged 18 to 75 years (19 to 75 years in korea) in phase ii part, either sex
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
2. patients diagnosed with hepatocellular carcinoma. the diagnosis of hcc (hepatocellular carcinoma) should be established by cytology or histopathology
Description

Liver carcinoma

Data type

boolean

Alias
UMLS CUI [1]
C2239176
3. patients who have unresectable hcc and meet all of the following conditions:
Description

Liver carcinoma | unresectable | Criteria Fulfill

Data type

boolean

Alias
UMLS CUI [1]
C2239176
UMLS CUI [2]
C1519810
UMLS CUI [3,1]
C0243161
UMLS CUI [3,2]
C1550543
barcelona clinic liver cancer (bclc) stage b or c
Description

BCLC Stage

Data type

boolean

Alias
UMLS CUI [1]
C3899974
transaarterial chemoembolization (tace) refractory in discretion of the investigators, or tace unsuitable (such as but not limited to portal vein thrombosis)
Description

Transarterial Chemoembolization Unresponsive to Treatment | Transarterial Chemoembolization Inappropriate | Portal vein thrombosis

Data type

boolean

Alias
UMLS CUI [1,1]
C3539919
UMLS CUI [1,2]
C0205269
UMLS CUI [2,1]
C3539919
UMLS CUI [2,2]
C1548788
UMLS CUI [3]
C0155773
local ablative treatment (such as percutaneous ethanol injection, radiofrequency ablation, etc) unsuitable
Description

Local ablation therapy Inappropriate | Percutaneous ethanol injection | Radiofrequency ablation

Data type

boolean

Alias
UMLS CUI [1,1]
C0547070
UMLS CUI [1,2]
C1548788
UMLS CUI [2]
C1535909
UMLS CUI [3]
C0850292
sorafenib failure, intolerable or ineligible
Description

Sorafenib failed | Intolerance to Sorafenib | Sorafenib Ineligible

Data type

boolean

Alias
UMLS CUI [1,1]
C1516119
UMLS CUI [1,2]
C0231175
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C1516119
UMLS CUI [3,1]
C1516119
UMLS CUI [3,2]
C1512714
4. patients must have at least one lesion that can be accurately measured in at least one dimension as 1 cm or more and the lesion must be suitable for repeat measurement
Description

Measurable lesion linear Quantity | Lesion Appropriate Measurement Repeated

Data type

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C0205132
UMLS CUI [1,3]
C1265611
UMLS CUI [2,1]
C0221198
UMLS CUI [2,2]
C1548787
UMLS CUI [2,3]
C0242485
UMLS CUI [2,4]
C0205341
5. patients who have child-pugh's score no greater than 7, and have no ascites
Description

Child-Pugh Classification | Ascites Absent

Data type

boolean

Alias
UMLS CUI [1]
C2347612
UMLS CUI [2,1]
C0003962
UMLS CUI [2,2]
C0332197
6. patients who have all the conditions below at screening:
Description

Patient Condition

Data type

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C0348080
serum alt (alanine aminotransferase) level (gpt) less than 2.5 x unl
Description

Alanine aminotransferase measurement

Data type

boolean

Alias
UMLS CUI [1]
C0201836
serum ast (aspartate aminotransferase) level (got) less than 2.5 x unl
Description

Aspartate aminotransferase measurement

Data type

boolean

Alias
UMLS CUI [1]
C0201899
wbc (white blood cell) greater than or equal to 3,000 / microliter
Description

White Blood Cell Count procedure

Data type

boolean

Alias
UMLS CUI [1]
C0023508
serum creatinine less than or equal to 1.5 x unl
Description

Creatinine measurement, serum

Data type

boolean

Alias
UMLS CUI [1]
C0201976
activated partial thromboplastin time (aptt) <1.5 x unl
Description

Activated Partial Thromboplastin Time measurement

Data type

boolean

Alias
UMLS CUI [1]
C0030605
7. platelet count correctable to greater than or equal to 80,000 / microliter
Description

Platelet Count measurement

Data type

boolean

Alias
UMLS CUI [1]
C0032181
8. prothrombin time-international normalized ratio (pt-inr) correctable to less than 1.5
Description

Prothrombin time international normalized ratio (PT-INR)

Data type

boolean

Alias
UMLS CUI [1]
C1821762
9. patients who have life expectancy longer than 12 weeks
Description

Life Expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. patients who have had chemotherapy within last three weeks (6 weeks for nitrosourea or mitomycin-c) prior to dosing
Description

Chemotherapy | Nitrosourea | Mitomycin

Data type

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C0028210
UMLS CUI [3]
C0002475
2. patients who have had radiotherapy to tumor site within the last four weeks prior to dosing and with documentation of subsequent tumor growth at this site
Description

Therapeutic radiology procedure Tumor site | Tumor growth subsequent

Data type

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C0475445
UMLS CUI [2,1]
C0598934
UMLS CUI [2,2]
C0332282
3. patients who have received other investigational or antineoplastic medication within the last four weeks prior to dosing
Description

Investigational New Drugs | Antineoplastic Agents

Data type

boolean

Alias
UMLS CUI [1]
C0013230
UMLS CUI [2]
C0003392
4. patients who had history of esophageal variceal bleeding within eight weeks prior to study entry
Description

Bleeding esophageal varices

Data type

boolean

Alias
UMLS CUI [1]
C0155789
5. patients who have uncontrolled diabetes, active or chronic infection, including hiv, except for asymptomatic bacterial colonization, hepatitis b virus (hbv), or hepatitis c virus (hcv) infection
Description

Diabetic - poor control | Communicable Disease | Chronic infectious disease | HIV Infection | Exception Bacterial colonisation Asymptomatic | Hepatitis B | Hepatitis C

Data type

boolean

Alias
UMLS CUI [1]
C0421258
UMLS CUI [2]
C0009450
UMLS CUI [3]
C0151317
UMLS CUI [4]
C0019693
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C2747813
UMLS CUI [5,3]
C0231221
UMLS CUI [6]
C0019163
UMLS CUI [7]
C0019196
6. patients who had acute viral infection syndrome diagnosed within the last two weeks
Description

Virus Disease

Data type

boolean

Alias
UMLS CUI [1]
C0042769
7. patients who have concomitant hematological malignancy (e.g. acute lymphocytic leukemia, non-hodgkin's lymphoma)
Description

Hematologic Neoplasms | Acute lymphocytic leukemia | Lymphoma, Non-Hodgkin

Data type

boolean

Alias
UMLS CUI [1]
C0376545
UMLS CUI [2]
C0023449
UMLS CUI [3]
C0024305
8. patients who have active rheumatoid arthritis or other autoimmune disease.
Description

Rheumatoid Arthritis | Autoimmune Diseases

Data type

boolean

Alias
UMLS CUI [1]
C0003873
UMLS CUI [2]
C0004364
9. patients who have current requirement for chronic systemic immunosuppressive medication including any dose of glucocorticoid or cyclosporin, or chronic use of any such medication within the last four weeks note: course of glucocorticoid therapy less than 10 days duration is allowed (e.g. for nausea control)
Description

Patient need for Immunosuppressive Agents systemic chronic | Glucocorticoids Dose Any | Cyclosporine Dose Any | Glucocorticoids chronic | Cyclosporine chronic

Data type

boolean

Alias
UMLS CUI [1,1]
C0686904
UMLS CUI [1,2]
C0021081
UMLS CUI [1,3]
C0205373
UMLS CUI [1,4]
C0205191
UMLS CUI [2,1]
C0017710
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C1552551
UMLS CUI [3,1]
C0010592
UMLS CUI [3,2]
C0178602
UMLS CUI [3,3]
C1552551
UMLS CUI [4,1]
C0017710
UMLS CUI [4,2]
C0205191
UMLS CUI [5,1]
C0010592
UMLS CUI [5,2]
C0205191
10. patients with organ transplants (may require prolonged immunosuppressive therapy)
Description

Organ Transplantation | Therapeutic immunosuppression Prolonged Required

Data type

boolean

Alias
UMLS CUI [1]
C0029216
UMLS CUI [2,1]
C0021079
UMLS CUI [2,2]
C0439590
UMLS CUI [2,3]
C1514873
11. patients who had prior participation in any research protocol which involved administration of adenovirus vectors
Description

Study Subject Participation Status | Adenoviral Vector

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C1510800
12. patients received any immune-related related related related related blood products, such as immunoglobulin in the prior 3 months
Description

Blood product Immune system Related | Immunoglobulins

Data type

boolean

Alias
UMLS CUI [1,1]
C0456388
UMLS CUI [1,2]
C0020962
UMLS CUI [1,3]
C0439849
UMLS CUI [2]
C0021027
13. patients who have uncontrolled concurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Description

Comorbidity Uncontrolled | Communicable Disease | Symptomatic congestive heart failure | Angina, Unstable | Cardiac Arrhythmia | Mental disorders Limiting Protocol Compliance | Social situation Limiting Protocol Compliance

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205318
UMLS CUI [2]
C0009450
UMLS CUI [3]
C0742758
UMLS CUI [4]
C0002965
UMLS CUI [5]
C0003811
UMLS CUI [6,1]
C0004936
UMLS CUI [6,2]
C0439801
UMLS CUI [6,3]
C0525058
UMLS CUI [7,1]
C0748872
UMLS CUI [7,2]
C0439801
UMLS CUI [7,3]
C0525058
14. psychiatric, addictive, or any disorder which compromises ability to give truly informed consent for participation in this study or adequate compliance
Description

Mental disorders compromise Informed Consent | Addictive Behavior compromises Informed Consent | Disease compromises Informed Consent | Mental disorders compromise Compliance behavior | Addictive Behavior compromises Compliance behavior | Disease compromises Compliance behavior

Data type

boolean

Alias
UMLS CUI [1,1]
C0004936
UMLS CUI [1,2]
C2945640
UMLS CUI [1,3]
C0021430
UMLS CUI [2,1]
C0085281
UMLS CUI [2,2]
C2945640
UMLS CUI [2,3]
C0021430
UMLS CUI [3,1]
C0012634
UMLS CUI [3,2]
C2945640
UMLS CUI [3,3]
C0021430
UMLS CUI [4,1]
C0004936
UMLS CUI [4,2]
C2945640
UMLS CUI [4,3]
C1321605
UMLS CUI [5,1]
C0085281
UMLS CUI [5,2]
C2945640
UMLS CUI [5,3]
C1321605
UMLS CUI [6,1]
C0012634
UMLS CUI [6,2]
C2945640
UMLS CUI [6,3]
C1321605
15. female patients that are pregnant or on breast-feeding
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
16. patients who receive anti-platelet agents or anti-coagulation agents (e.g. heparin, warfarin, aspirin, ticlopidine, clopidogrel, dipyridamole and so on).
Description

Antiplatelet Agents | Anticoagulants | heparin | Warfarin | Aspirin | Ticlopidine | clopidogrel | Dipyridamole

Data type

boolean

Alias
UMLS CUI [1]
C0085826
UMLS CUI [2]
C0003280
UMLS CUI [3]
C0019134
UMLS CUI [4]
C0043031
UMLS CUI [5]
C0004057
UMLS CUI [6]
C0040207
UMLS CUI [7]
C0070166
UMLS CUI [8]
C0012582
Back to the top of the page

Similar models

Eligibility Carcinoma, Hepatocellular NCT02293850

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
1. patients aged 18 to 65 years (19 to 65 years in korea) in phase i part or aged 18 to 75 years (19 to 75 years in korea) in phase ii part, either sex
boolean
C0001779 (UMLS CUI [1])
Liver carcinoma
Item
2. patients diagnosed with hepatocellular carcinoma. the diagnosis of hcc (hepatocellular carcinoma) should be established by cytology or histopathology
boolean
C2239176 (UMLS CUI [1])
Liver carcinoma | unresectable | Criteria Fulfill
Item
3. patients who have unresectable hcc and meet all of the following conditions:
boolean
C2239176 (UMLS CUI [1])
C1519810 (UMLS CUI [2])
C0243161 (UMLS CUI [3,1])
C1550543 (UMLS CUI [3,2])
BCLC Stage
Item
barcelona clinic liver cancer (bclc) stage b or c
boolean
C3899974 (UMLS CUI [1])
Transarterial Chemoembolization Unresponsive to Treatment | Transarterial Chemoembolization Inappropriate | Portal vein thrombosis
Item
transaarterial chemoembolization (tace) refractory in discretion of the investigators, or tace unsuitable (such as but not limited to portal vein thrombosis)
boolean
C3539919 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C3539919 (UMLS CUI [2,1])
C1548788 (UMLS CUI [2,2])
C0155773 (UMLS CUI [3])
Local ablation therapy Inappropriate | Percutaneous ethanol injection | Radiofrequency ablation
Item
local ablative treatment (such as percutaneous ethanol injection, radiofrequency ablation, etc) unsuitable
boolean
C0547070 (UMLS CUI [1,1])
C1548788 (UMLS CUI [1,2])
C1535909 (UMLS CUI [2])
C0850292 (UMLS CUI [3])
Sorafenib failed | Intolerance to Sorafenib | Sorafenib Ineligible
Item
sorafenib failure, intolerable or ineligible
boolean
C1516119 (UMLS CUI [1,1])
C0231175 (UMLS CUI [1,2])
C1744706 (UMLS CUI [2,1])
C1516119 (UMLS CUI [2,2])
C1516119 (UMLS CUI [3,1])
C1512714 (UMLS CUI [3,2])
Measurable lesion linear Quantity | Lesion Appropriate Measurement Repeated
Item
4. patients must have at least one lesion that can be accurately measured in at least one dimension as 1 cm or more and the lesion must be suitable for repeat measurement
boolean
C1513041 (UMLS CUI [1,1])
C0205132 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0221198 (UMLS CUI [2,1])
C1548787 (UMLS CUI [2,2])
C0242485 (UMLS CUI [2,3])
C0205341 (UMLS CUI [2,4])
Child-Pugh Classification | Ascites Absent
Item
5. patients who have child-pugh's score no greater than 7, and have no ascites
boolean
C2347612 (UMLS CUI [1])
C0003962 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Patient Condition
Item
6. patients who have all the conditions below at screening:
boolean
C0030705 (UMLS CUI [1,1])
C0348080 (UMLS CUI [1,2])
Alanine aminotransferase measurement
Item
serum alt (alanine aminotransferase) level (gpt) less than 2.5 x unl
boolean
C0201836 (UMLS CUI [1])
Aspartate aminotransferase measurement
Item
serum ast (aspartate aminotransferase) level (got) less than 2.5 x unl
boolean
C0201899 (UMLS CUI [1])
White Blood Cell Count procedure
Item
wbc (white blood cell) greater than or equal to 3,000 / microliter
boolean
C0023508 (UMLS CUI [1])
Creatinine measurement, serum
Item
serum creatinine less than or equal to 1.5 x unl
boolean
C0201976 (UMLS CUI [1])
Activated Partial Thromboplastin Time measurement
Item
activated partial thromboplastin time (aptt) <1.5 x unl
boolean
C0030605 (UMLS CUI [1])
Platelet Count measurement
Item
7. platelet count correctable to greater than or equal to 80,000 / microliter
boolean
C0032181 (UMLS CUI [1])
Prothrombin time international normalized ratio (PT-INR)
Item
8. prothrombin time-international normalized ratio (pt-inr) correctable to less than 1.5
boolean
C1821762 (UMLS CUI [1])
Life Expectancy
Item
9. patients who have life expectancy longer than 12 weeks
boolean
C0023671 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Chemotherapy | Nitrosourea | Mitomycin
Item
1. patients who have had chemotherapy within last three weeks (6 weeks for nitrosourea or mitomycin-c) prior to dosing
boolean
C0392920 (UMLS CUI [1])
C0028210 (UMLS CUI [2])
C0002475 (UMLS CUI [3])
Therapeutic radiology procedure Tumor site | Tumor growth subsequent
Item
2. patients who have had radiotherapy to tumor site within the last four weeks prior to dosing and with documentation of subsequent tumor growth at this site
boolean
C1522449 (UMLS CUI [1,1])
C0475445 (UMLS CUI [1,2])
C0598934 (UMLS CUI [2,1])
C0332282 (UMLS CUI [2,2])
Investigational New Drugs | Antineoplastic Agents
Item
3. patients who have received other investigational or antineoplastic medication within the last four weeks prior to dosing
boolean
C0013230 (UMLS CUI [1])
C0003392 (UMLS CUI [2])
Bleeding esophageal varices
Item
4. patients who had history of esophageal variceal bleeding within eight weeks prior to study entry
boolean
C0155789 (UMLS CUI [1])
Diabetic - poor control | Communicable Disease | Chronic infectious disease | HIV Infection | Exception Bacterial colonisation Asymptomatic | Hepatitis B | Hepatitis C
Item
5. patients who have uncontrolled diabetes, active or chronic infection, including hiv, except for asymptomatic bacterial colonization, hepatitis b virus (hbv), or hepatitis c virus (hcv) infection
boolean
C0421258 (UMLS CUI [1])
C0009450 (UMLS CUI [2])
C0151317 (UMLS CUI [3])
C0019693 (UMLS CUI [4])
C1705847 (UMLS CUI [5,1])
C2747813 (UMLS CUI [5,2])
C0231221 (UMLS CUI [5,3])
C0019163 (UMLS CUI [6])
C0019196 (UMLS CUI [7])
Virus Disease
Item
6. patients who had acute viral infection syndrome diagnosed within the last two weeks
boolean
C0042769 (UMLS CUI [1])
Hematologic Neoplasms | Acute lymphocytic leukemia | Lymphoma, Non-Hodgkin
Item
7. patients who have concomitant hematological malignancy (e.g. acute lymphocytic leukemia, non-hodgkin's lymphoma)
boolean
C0376545 (UMLS CUI [1])
C0023449 (UMLS CUI [2])
C0024305 (UMLS CUI [3])
Rheumatoid Arthritis | Autoimmune Diseases
Item
8. patients who have active rheumatoid arthritis or other autoimmune disease.
boolean
C0003873 (UMLS CUI [1])
C0004364 (UMLS CUI [2])
Patient need for Immunosuppressive Agents systemic chronic | Glucocorticoids Dose Any | Cyclosporine Dose Any | Glucocorticoids chronic | Cyclosporine chronic
Item
9. patients who have current requirement for chronic systemic immunosuppressive medication including any dose of glucocorticoid or cyclosporin, or chronic use of any such medication within the last four weeks note: course of glucocorticoid therapy less than 10 days duration is allowed (e.g. for nausea control)
boolean
C0686904 (UMLS CUI [1,1])
C0021081 (UMLS CUI [1,2])
C0205373 (UMLS CUI [1,3])
C0205191 (UMLS CUI [1,4])
C0017710 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C1552551 (UMLS CUI [2,3])
C0010592 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C1552551 (UMLS CUI [3,3])
C0017710 (UMLS CUI [4,1])
C0205191 (UMLS CUI [4,2])
C0010592 (UMLS CUI [5,1])
C0205191 (UMLS CUI [5,2])
Organ Transplantation | Therapeutic immunosuppression Prolonged Required
Item
10. patients with organ transplants (may require prolonged immunosuppressive therapy)
boolean
C0029216 (UMLS CUI [1])
C0021079 (UMLS CUI [2,1])
C0439590 (UMLS CUI [2,2])
C1514873 (UMLS CUI [2,3])
Study Subject Participation Status | Adenoviral Vector
Item
11. patients who had prior participation in any research protocol which involved administration of adenovirus vectors
boolean
C2348568 (UMLS CUI [1])
C1510800 (UMLS CUI [2])
Blood product Immune system Related | Immunoglobulins
Item
12. patients received any immune-related related related related related blood products, such as immunoglobulin in the prior 3 months
boolean
C0456388 (UMLS CUI [1,1])
C0020962 (UMLS CUI [1,2])
C0439849 (UMLS CUI [1,3])
C0021027 (UMLS CUI [2])
Comorbidity Uncontrolled | Communicable Disease | Symptomatic congestive heart failure | Angina, Unstable | Cardiac Arrhythmia | Mental disorders Limiting Protocol Compliance | Social situation Limiting Protocol Compliance
Item
13. patients who have uncontrolled concurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
boolean
C0009488 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2])
C0742758 (UMLS CUI [3])
C0002965 (UMLS CUI [4])
C0003811 (UMLS CUI [5])
C0004936 (UMLS CUI [6,1])
C0439801 (UMLS CUI [6,2])
C0525058 (UMLS CUI [6,3])
C0748872 (UMLS CUI [7,1])
C0439801 (UMLS CUI [7,2])
C0525058 (UMLS CUI [7,3])
Mental disorders compromise Informed Consent | Addictive Behavior compromises Informed Consent | Disease compromises Informed Consent | Mental disorders compromise Compliance behavior | Addictive Behavior compromises Compliance behavior | Disease compromises Compliance behavior
Item
14. psychiatric, addictive, or any disorder which compromises ability to give truly informed consent for participation in this study or adequate compliance
boolean
C0004936 (UMLS CUI [1,1])
C2945640 (UMLS CUI [1,2])
C0021430 (UMLS CUI [1,3])
C0085281 (UMLS CUI [2,1])
C2945640 (UMLS CUI [2,2])
C0021430 (UMLS CUI [2,3])
C0012634 (UMLS CUI [3,1])
C2945640 (UMLS CUI [3,2])
C0021430 (UMLS CUI [3,3])
C0004936 (UMLS CUI [4,1])
C2945640 (UMLS CUI [4,2])
C1321605 (UMLS CUI [4,3])
C0085281 (UMLS CUI [5,1])
C2945640 (UMLS CUI [5,2])
C1321605 (UMLS CUI [5,3])
C0012634 (UMLS CUI [6,1])
C2945640 (UMLS CUI [6,2])
C1321605 (UMLS CUI [6,3])
Pregnancy | Breast Feeding
Item
15. female patients that are pregnant or on breast-feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Antiplatelet Agents | Anticoagulants | heparin | Warfarin | Aspirin | Ticlopidine | clopidogrel | Dipyridamole
Item
16. patients who receive anti-platelet agents or anti-coagulation agents (e.g. heparin, warfarin, aspirin, ticlopidine, clopidogrel, dipyridamole and so on).
boolean
C0085826 (UMLS CUI [1])
C0003280 (UMLS CUI [2])
C0019134 (UMLS CUI [3])
C0043031 (UMLS CUI [4])
C0004057 (UMLS CUI [5])
C0040207 (UMLS CUI [6])
C0070166 (UMLS CUI [7])
C0012582 (UMLS CUI [8])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial